MPTP mouse models of Parkinson's disease: An update

Journal of Parkinson's Disease

Volumn 1, Issue 1, 2011, Pages 19-33

  Meredith, Gloria E ^a   Rademacher, David J ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

C57 BL mouse; dopamine; grid test; hydropyridine; open field; rotarod; substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM CHANNEL; INDUCIBLE NITRIC OXIDE SYNTHASE; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; PROTEIN BCL 2; PROTEIN P35;

ANIMAL BEHAVIOR; APOPTOSIS; BEHAVIOR DISORDER; CELL FUNCTION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG MECHANISM; GENE IDENTIFICATION; HUMAN; MITOCHONDRION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; STRAIN DIFFERENCE;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; MICE; PARKINSONIAN DISORDERS;

EID: 79958214912     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11023     Document Type: Review

References (165)

1. Di Monte D, Sandy MS, Ekstr̈om G, & Smith MT (1986) Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem Biophys Res Comm, 137, 303-309. (Pubitemid 16056066)
2. McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, & Marsden CD (1996) Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. Biochem Pharmacol, 51, 1503-1511.
3. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, & Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3, 1301-1306.
4. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, & FederoffHJ (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res, 823, 1-10. (Pubitemid 29225488)
5. Chun HS, Gibson GE, DeGiorgio LA, Zhang H, Kidd VJ, & Son JH (2001) Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem, 76, 1010-1021. (Pubitemid 32167374)
6. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, & Cory-Slechta DA (2000) The nigrostriatal dopamine system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci, 20, 9207-9214. (Pubitemid 32042923)
7. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, & Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res, 1, 249-254. (Pubitemid 10123385)
8. Langston JW, Forno LS, Rebert CS, & Irwin I (1984) Selective nigral toxicity after systemic administration of 1- methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res, 292, 390-394. (Pubitemid 14190114)
9. Sonsalla PK & Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol, 129, 339-345. (Pubitemid 16008029)
10. Marini AM, Lipsky RH, Schwartz JP, & Kopin IJ (1992) Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J Neurochem, 58, 1250-1258.
11. Lau Y-S, Fung YK, Trobough KL, Cashman JR, & Wilson JA (1991) Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)- treated mice. Neurotoxicology, 12, 189-199.
12. Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, & Zeevalk GD (2006) Rat model of Parkinson's disease: Chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp Neurol, 200, 172-183. (Pubitemid 44080759)
13. Nicklas WJ, Vyas I, & Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1- methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci, 36, 2503-2508. (Pubitemid 15072756)
14. Ramsay RR, Dadgar J, Trevor A, & Singer TP (1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the toxicity of MPTP. Life Sci, 39, 581-588. (Pubitemid 16040078)
15. Sayre LM,Wang F, & Hoppel CL (1989) Tetraphenylborate potentiates the respiratory inhibition by the dopaminergic neurotoxin MPP+ in both electron transport particles and intact mitochondria. Biochem Biophys Res Comm, 161, 809-818. (Pubitemid 19162706)
16. Przedborski S & Jackson-Lewis V (1998) Mechanisms of MPTP toxicity. Mov Disord, 13, 35-38.
17. Chan P, DeLanney LE, Irwin I, Langston JW, & Di Monti D (1991) Rapid ATP loss caused by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem, 57, 348-351.
18. Davey GP, Peuchen S, & Clark JB (1998) Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem, 273, 12753-12757. (Pubitemid 28246828)
19. Jackson-Lewis V, Jakowec M, Burke RE, & Przedborski S (1995) Time course and morphology of dopaminergic neuronal cell death caused by the neurotoxin 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration, 4, 257-269.
20. Irwin I, DeLanney LE, & Langston JW (1993) MPTP and aging. Studies in the C57BL/6 mouse. Adv Neurol, 60, 197-206.
21. Chan P, DeLanney LE, Irwin I, Langston JW, & Di Monte D (1991) Rapid ATP loss caused by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem, 57, 348-351.
22. Chan P, Langston JW, Irwin I, DeLanney LE, & Di Monte DA (1993) 2-Deoxyglucose enhances 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse brain. J Neurochem, 61, 610-616. (Pubitemid 23215806)
23. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, & Forno LS (1986) Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res, 376, 117-124. (Pubitemid 16046022)
24. Janson AM, Fuxe K, Sunderstr̈om E, Agnati LF, & Goldstein M (1988) Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand, 132, 589-591.
25. Chadi G, Moller A, Rosen L, Janson AM, Agnati LA, Goldstein M, Ogren S-O, Pettersson RF, & Fuxe K (1993) Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp Brain Res, 97, 145-158. (Pubitemid 24045430)
26. Gerlach M & Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm, 103, 987-1041. (Pubitemid 26383833)
27. Zang LY & Misra HP (1993) Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Biol Chem, 268, 16504-16512. (Pubitemid 23229958)
28. Muralikrishnan D & Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J, 12, 905-912. (Pubitemid 28294680)
29. Obata T & Chiueh CC (1992) In vivo trapping of hydroxyl free radicals in the striatum using intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+. J Neural Transm Gen Sect, 89, 139-145.
30. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl, 126, 23-33. (Pubitemid 20022073)
31. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem, 59, 1609-1623.
32. G̈otz ME,K̈unig G, Riederer P & Youdim MB(1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther, 63, 37-122. (Pubitemid 24250150)
33. Dedon PC, Plastaras JP, Rouzer CA, & Marnett LJ (1998) Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal. Proc Natl Acad Sci USA, 95, 11113-11116. (Pubitemid 28450090)
34. Obata T, Yamanaka Y, Kinemuchi H, & Oreland L (2001) Release of dopamine by perfusion with 1-methyl- 4-phenylpyridinium ion (MPP(+)) into the striatum is associated with hydroxyl free radical generation. Brain Res, 906, 170-175. (Pubitemid 32595552)
35. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Yamada M, Tamayose K, Shimada T, Miura M, & Mizuno Y (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA, 98, 10918-10923. (Pubitemid 32878719)
36. ViswanathV,WuY, Boonplueang R, Chen S, Stevensson FF, Yantiri F, Beal MF, & Andersen JK (2001) Caspase-9 activation results in downstream caspase-8 activation and Bid cleavage in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridineinduced Parkinson's disease. J Neurosci, 21, 9519-9528. (Pubitemid 34184040)
37. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, & Beal MF (1998) 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity is attenuated in mice overexpressing Bcl-2 . J Neurosci, 18, 8145-8152. (Pubitemid 28464993)
38. Cassarino DS, Parks JK, Parker WD Jr, & Bennett JP Jr (1999) The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta, 1453, 49-62. (Pubitemid 29065457)
39. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, & Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf- 1-mediated oligomerization. Mol Cell, 1, 949-957. (Pubitemid 128379256)
40. Teng X, Sakai T, Liu L, Sakai R, Kaji R, & Fukui K (2006) Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in nucling-deficient mice via suppression of the apoptosome pathway. J Neurochem, 97, 1126-1135.
41. Meredith GE, Totterdell S, Beales M, & Meshul CK (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol, 219, 334-340.
42. Sonsalla PK, Albers DS, & Zeevalk GD (1998) Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids, 14, 69-74. (Pubitemid 28051154)
43. Turski L, Bressler K, Rettig KJ, L̈oschmann PA, & Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 349, 414-418. (Pubitemid 21926101)
44. Novelli A, Reilly JA, Lysko PG, & Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl- D-aspartate receptor when intracellular energy levels are reduced. Brain Res, 451, 205-212.
45. Perier C, Tieu K, Gúegan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, & Villa M(2005) Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA, 102, 19126-19131. (Pubitemid 43049577)
46. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, & Beal MF (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med, 2, 1017-1021. (Pubitemid 26306841)
47. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, & Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA, 93, 4565-4571.
48. Beckman JS & Crow JP (1993) Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans, 21, 330-334. (Pubitemid 23167917)
49. Dawson VL & Dawson TM (1996) Nitric oxide neurotoxicity. J Chem Neuroanat, 10, 179-190. (Pubitemid 26197684)
50. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, & Dawson TM (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)- induced parkinsonism. Proc Natl Acad Sci USA, 96, 5774-5779. (Pubitemid 29234694)
51. Zhang J, Dawson VL, Dawson TM, & Snyder SH (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science, 263, 687-689. (Pubitemid 24076297)
52. Cosi C & Marien M (1998) Decrease in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res, 809, 58-67. (Pubitemid 29003426)
53. Cosi C & Marien M (1999) Implication of poly (ADPribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann NY Acad Sci, 890, 227-239. (Pubitemid 30040381)
54. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, & DawsonVL(2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science, 297, 259-263. (Pubitemid 34761289)
55. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, & Kroemer G (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 397, 441-446.
56. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Pŕevost MC, Leber B, Andrews D, Penninger J, & Kroemer G (2000) Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J, 14, 729-739. (Pubitemid 30198571)
57. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, Ferri KF, Zamzani N, Wakeham A, Hakem R, Yoshida H, Kong YY, Mak TW, Źuñiga-Pfl̈ucker JC, Kroemer G, & Penninger JM (2001) Essential role of the mitochondrial apoptosisinducing factor in programmed cell death. Nature, 410, 549-554. (Pubitemid 32267191)
58. Kurkowska-Jastrzebska I, Balkowiec-Iskra E, Ciesielska A, Joniec I, Cudna A, Zaremba MM, Czlonkowski A, & Czlonkowska A (2009) Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease. Int Immunopharmacol, 9, 781-791.
59. Banati RB, Gehrmann J, Schubert P, & Kreutzberg GW (1993) Cytotoxicity of microglia. Glia, 7, 111-118.
60. Costaño A, Herrera AJ, Cano J, & Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem, 70, 1584-1592. (Pubitemid 28136972)
61. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, & Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81, 1285-1297. (Pubitemid 34809262)
62. Furuya T, Hayakawa H, Yamada M, Yoshima K, Hisahara S, Miura M, Mizuno Y, & Mochizuki H (2004) Caspase-11 mediates inflammatory dopaminergic cell death in the 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci, 24, 1865-1872. (Pubitemid 38292797)
63. Meredith GE, Dervan A, & Totterdell S (2005) Activated microglia persist in the substantia nigra of a chronic MPTP mouse model of Parkinson's disease. Adv Beh Biol, 56, 341-347.
64. Meredith GE, Halliday GM, & Totterdell S (2004) A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into lewy body formation. Parkinsonism Rel Disord, 10, 191-202. (Pubitemid 38534612)
65. Kawasaki T, Ago Y, Kitao T, Nashida T, Takagi A, Takuma K, & Matsuda T (2008) A neuroprotective agent, T-817MA (1-3-[2-(1-benzothiophen-5- yl)ethoxy]propyl azetidin-3-ol maleate), prevents 1-methyl- 4-phenyl-1,2,3,6- tetrahydropyridine-induced toxicity in mice. Neuropharmacology, 55, 654-660.
66. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, & Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci, 22, 1763-1771. (Pubitemid 35386294)
67. Dehmer T, Lindenau J, Haid S, Dichgans J, & Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects againstMPTPtoxicity in vivo. J Neurochem, 74, 2213-2216. (Pubitemid 30217680)
68. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG,Dawson VL, Dawson TM, & Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med, 5, 1403-1409.
69. Sherman MY & Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32. (Pubitemid 32108719)
70. McNaught KS, PerlDP, Brownell AL, & OlanowCW(2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol, 56, 149-162. (Pubitemid 38857373)
71. Fornai F, Schl̈uter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, & S̈udhof TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA, 102, 3413-3418. (Pubitemid 40328059)
72. Kodoguchi N, Kimoto H,Yano R, Kato H, & Araki T (2008) Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice. Metab Brain Dis, 23, 147-154.
73. Kodoguchi N, Umeda M, Kato H, & Araki T (2008) Proteasome inhibitor does not enhance MPTP neurotoxicity in mice. Cell Mol Neurobiol, 28, 971-979.
74. Oshikawa T, Kuroiwa H, Yano R, Yokoyama H, Kadoguchi N, Kato H, & Araki T (2009) Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice. Cell Mol Neurobiol, 29, 769-777.
75. Forno LS, DeLanney LE, Irwin I, & Langston JW (1993) Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv Neurol, 60, 600-608.
76. Heikkila RE, Hess A, & Duvoisin RC (1984) Dopaminergic toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science, 224, 1451-1453. (Pubitemid 14123348)
77. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, & Przedborski S (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem, 74, 721-729. (Pubitemid 30053745)
78. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC, & Lau YS JJr (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res, 956, 156-165. (Pubitemid 35335568)
79. Donnan GA, Kaczmarczyk SJ, Solopotias T, Rowe P, Kalnins RM, Vajda FJ, & Mendelsohn FA (1986) The neurochemical and clinical effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in small animals. Clin Exp Neurol, 22, 155-164.
80. Hamre K, Tharp R, Poon K, Xiong X, & Smeyne RJ (1999) Differential strain susceptibility following 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus Musculus. Brain Res, 828, 91-103. (Pubitemid 29236478)
81. Jackson-Lewis V & Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols, 2, 141-151. (Pubitemid 47044700)
82. Mitra N, Mohanakumar KP, & Ganguly DK (1994) Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. B J Neurochem, 62, 1906-1912.
83. Riachi NJ & Harik SI (1988) Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci 42, 2359-2363.
84. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, & Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behavior Genetics, 30, 171-182.
85. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, & Schwarting RK (2000) Evidence for resistance to MPTP in C57BL/6 X BALB/c F1 hybrids as compared with their progenitor strains. Neuroreport, 11, 1093-1096. (Pubitemid 30235461)
86. Sunderstr̈om E, Str̈omberg I, Tsutsumi T, Olson L, & Johsson G (1987) Studies on the effect of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res, 405, 26-38. (Pubitemid 17034929)
87. Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, & Przedborski S. (1994) Differences in nigral neuron number and sensitivity to 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/BL and CD-1 mice. Exper Neurol, 126, 195-204. (Pubitemid 24182041)
88. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, & Sonsalla PK (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration, 5, 299-312. (Pubitemid 27077888)
89. Sedelis M, Hofele K, Schwarting RK, Huston JP, & Belknap JK (2003) Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Neurosci, 23, 8247-8253. (Pubitemid 37129641)
90. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, & Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci, 16, 135-142. (Pubitemid 30159159)
91. Inoue H, Castagnoli K, Van Der Schyf C, Mabic S, Igarashi K, & Castagnoli N Jr (1999) Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methy-4-phenyl- 1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther, 291, 856-864. (Pubitemid 29503562)
92. Andersen JK, Frim DM, Isacson O, Beal MF, & Breakefield XO (1994) Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Brain Res, 656, 108-114. (Pubitemid 24263035)
93. Kilbourn M & Frey K (1996) Striatal concentrations of vesicular monoamine transporters are identical in MPTPsensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol, 307, 227-232. (Pubitemid 26226227)
94. Ali SF, David SN, & Newport GD (1993) Age-related susceptibility to MPTP-induced neurotoxicology in mice. Neurotoxicology, 14, 29-34. (Pubitemid 23195761)
95. Ali SF, David SN, Newport GD, Cadet JL, & Slikker W Jr (1994) MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18, 27-34. (Pubitemid 24279144)
96. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, & Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci, 12, 1658-1667.
97. Andrews AM, Ladenheim B, Epstein CJ, Cadet JL, & Murphy DL (1996) Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol, 50, 1511-1519.
98. Andrews AM & MurphyDL (1993) 2'-NH2-MPTP in Swiss Weber mice: evidence for long-term (6-months) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. J Pharmacol Exp Ther, 267, 1432-1439. (Pubitemid 24068718)
99. Andrews AM & Murphy DL (1993) Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)- 1,2,3,6-tetrahydropyridine (2'-NH2-MPTP): a comparative study with 2'-CH3-MPTP and MPTP. J Neurochem, 60, 1167-1170. (Pubitemid 23066744)
100. Gainetdinov RR, Fumagalli F, Jones SR, & Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem, 69, 1322-1325. (Pubitemid 27364858)
101. Womer DE, Jones BC, & ErwinVG(1994) Characterization of dopamine transporter and locomotor effects of cocaine, GBR 12909, epidepride, and SCH 23390 in C57BL and DBA mice. Pharmacol Biochem Behav, 48, 327-335. (Pubitemid 24197347)
102. Hazell AS, Itzhak Y, Liu H, & Norenberg MD (1997) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyradine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem, 68, 2216-2219. (Pubitemid 27176161)
103. Kupsch A, Gerlach M, Pupeter SC, Sautterx J, Dirr A, Arnold G, Opitz W, Przuntek H, Riederer P, & Oertel WH (1995) Pretreatment with nimodipine prevents MPTP- induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport, 6, 621-625.
104. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, & Parker WD Jr (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40, 663-671. (Pubitemid 26357892)
105. Hoskins JA & Davis LJ (1989) The acute effect on levels of catecholamines and metabolites in the brain of a single dose of MPTP in 8 strains of mice. Neuropharmacology, 28, 1389-1397. (Pubitemid 20008276)
106. Schwarting RK, Sedelis M, Hofele K, Auburger GW, & Huston JP (1999) Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res, 1, 41-56.
107. Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, & Schwarting RKW (2001) Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exper Neurol 168, 116-122. (Pubitemid 32195263)
108. Festing MF (1991) Genetic factors in neurotoxicology and neuropharmacology: a critical evaluation of the use of genetics as a research tool. Experientia, 47, 990-998.
109. Schapira AH (1993) Mitochondrial complex I deficiency in Parkinson's disease. Adv Neurol, 60, 288-291.
110. Petroske E, Meredith GE, Callen S, Totterdell S, & Lau YS (2001) Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience, 106, 589-601. (Pubitemid 32925247)
111. Meredith GE & Kang UJ (2006) Behavioral models of Parkinson's disease in rodents: a newlook at an old problem. Mov Disord, 21, 1595-1606. (Pubitemid 44742185)
112. Dauer W & Przedborski S (2003) Parkinson's disease: Mechanisms and models. Neuron, 39, 889-909. (Pubitemid 37130207)
113. Dawson TM & Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822. (Pubitemid 37339614)
114. Meredith GE, Sonsalla PK, & Chesselet M-F (2008) Animal models of Parkinson's disease progression. Acta Neuropathol, 115, 385-398.
115. Hallman H, Lange J, Olson L, Stromberg I, & Jonsson G (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem, 44, 117-127.
116. Bezard E, Dovero S, Bioulac B, & Gross CE (1997) Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett, 234, 47-50. (Pubitemid 27435966)
117. Shimoji M, Zhang L, Mandir AS, Dawson VL, & Dawson TM (2005) Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res Mol Brain Res, 1345, 103-108. (Pubitemid 40403642)
118. Tatton NA & Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labeling and acridine orange staining. Neuroscience, 77, 1037-1048.
119. Gibrat C, Saint-Pierre M, Bousquet M, Ĺevesque D, Rouillard C, & Cicchetti F (2009) Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem, 109, 1469-1482.
120. Novikova L, Garris BL, Garris DR, & Lau YS (2006) Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience, 140, 67-76. (Pubitemid 43668437)
121. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC, & Lau YS Jr (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res, 956, 156-165. (Pubitemid 35335568)
122. Xu Z, Cawthon D, McCastlain KA, Slikker W, & Ali SF Jr (2005) Selective alterations of gene expression in mice induced by MPTP. Synapse, 55, 45-51. (Pubitemid 39571769)
123. Goldberg NRS, Haack AK, Lim NS, Janson DK, & Meshul CK (2011) Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 180, 256-271.
124. Greenamyre JT & Hastings TG (2004) Parkinson's - divergent causes, convergent mechanisms. Science, 304, 1120-1122. (Pubitemid 38661838)
125. Barron KD (1995) The microglial cell. A historical review. J Neurol Sci, 134, 57-68.
126. Block ML, Zecca L, & Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci, 8, 57-69. (Pubitemid 46011999)
127. Liu B, Du L & Hong JS (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther, 293, 607-617. (Pubitemid 30244114)
128. McGeer PL, Schwab C, Parent A, & Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol, 54, 599-604. (Pubitemid 37346066)
129. Gao HM, Liu B, & Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci, 23, 6181-6187. (Pubitemid 36875618)
130. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, & Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol, 46, 598-605. (Pubitemid 29466438)
131. Kurkowska-Jastrzebska I, Wŕonska A, Kohutnicka M, Czlonkowski A, & Czlonkowski A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine intoxication in mouse. Exp Neurol, 156, 50-61.
132. Luchtman DW, Shao D, & Song C (2009) Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol, 98, 130-138.
133. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, & Felten DL Jr (1986) Aged mice are more sensitive to 1- methyl-4-phenyl-1,2,3,6- tetrahydropyridine treatment than young adults. Neurosci Lett, 70, 326-331. (Pubitemid 16024875)
134. Cenci MA, WhishawIQ, & Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci, 3, 574-579. (Pubitemid 135706667)
135. Arai N, Misugi K, Goshima Y, & Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated C57 black mouse model for parkinsonism. Brain Res, 515, 57-63. (Pubitemid 20176095)
136. Fredriksson A, Palomo T, & Archer T (1999) Effects of coadministration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice. J Neural Transm, 106, 889-909. (Pubitemid 29516058)
137. Willis GL & Donnan GA (1987) Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res, 402, 269-274. (Pubitemid 17005295)
138. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, & Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature, 373, 335-339.
139. Chia LG, Ni DR, Cheng LJ, Kuo JS, Cheng FC, & Dryhurst G (1996) Effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett, 218, 67-71. (Pubitemid 26366718)
140. Rozas G, Guerra MJ, & Labandeira-Garcia JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Protoc, 2, 75-84. (Pubitemid 28277496)
141. Rozas G & Labandeira-Garcia JL (1997) Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res, 749, 188-199. (Pubitemid 27104199)
142. Whishaw IQ, Li K, Whishaw PA, Gorny B, & Metz GA (2003) Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking. J Neurosci Methods, 126, 13-23. (Pubitemid 36683053)
143. OgawaN, HiroseY, Ohara S, OnoT, & WatanabeY(1985)A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol, 50, 435-441.
144. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, & Surmeier DJ (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 447, 1081-1086. (Pubitemid 47014425)
145. Tillerson JL & Miller GW (2002) Forced limb-use and recovery following brain injury. Neuroscientist, 8, 574-585. (Pubitemid 35379452)
146. Blume SR, Cass DK, & Tseng KY (2009) Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced parkinsonism. Exp Neurol, 219, 208-211.
147. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, & Wall RA (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett, 60, 109-114. (Pubitemid 16229764)
148. Tatton WG & Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res, 30, 666-672.
149. Thiffault C, Aumont N, Quirion R, & Poirier J (1995) Effect of MPTP and l-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem, 65, 2725-2733. (Pubitemid 3002930)
150. Kitamura Y, Kakimura J, & Taniguchi T (2002) Antiparkinsonian drugs and their neuroprotective effects. Biol Pharm Bull, 25, 284-290. (Pubitemid 39663277)
151. Chao CC, Hu S, Molitor TW, Shaskan EG, & Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol, 149, 2736-2741.
152. Hunot S, Boissìere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, & Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 72, 355-363. (Pubitemid 26111202)
153. Le W, Rowe D, Xie W, Ortiz I, He Y, & Appel SH (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci, 21, 8447-8455. (Pubitemid 33051443)
154. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, & Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem, 82, 615-624. (Pubitemid 34831499)
155. Lin S, Wei X, Xu Y, Yan C, Dodel R, Zhang Y, Liu J, Klaunig JE, Farlow M, & Du Y (2003) Minocycline blocks 6-hydroxydopamine-ionduced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci, 72, 1635-1641. (Pubitemid 36120789)
156. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Trarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, & Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA, 98, 14669-14674. (Pubitemid 33121449)
157. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, & Albers DS (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res, 74, 278-285. (Pubitemid 37193714)
158. Chan P, Di Monte DA, Langston JW, & Janson AM (1997) (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharm Exp Ther, 280, 439-446. (Pubitemid 27171432)
159. Kupsch A, L̈oshmann PA, Sauer H, Arnold G, Renner P, Pufal D, Burg M, Wachtel H, ten Bruggencate G, & Oertel WH (1992) Do NMDA antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res, 592, 74-83.
160. Santiago M, Venero JL, Machado A, & Cano J (1992) In vivo protection of striatum from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Brain Res, 586, 203-207.
161. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, & Nicklas WJ (1992) MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem, 58, 1979-1982.
162. Turski L, Bressler K, Rettig KJ, L̈oschmann PA, & Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 349, 414-418. (Pubitemid 21926101)
163. Mercuri NB, Bonci A, Calebresi P, Stratta F, Stefani A, & Bernardi G (1994) Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br J Pharmacol, 113, 831-838. (Pubitemid 24326822)
164. Nedergaard S, Flatman JA, & Engberg I (1993) Nifedipineand omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol, 466, 727-747. (Pubitemid 23225251)
165. Shepard PD & Stump D (1999) Nifedipine blocks apamininduced bursting activity in nigral dopamine-containing neurons. Brain Res, 817, 104-109. (Pubitemid 29225350)